Alexej Ballhausen, MD, Charité, Berlin, Germany, discusses unmet needs in RAS wild-type metastatic colorectal cancer (mCRC). Further research needs to be conducted to optimize maintenance therapy after first line panitumumab and FOLFOXIRI or FOLFOX. Dr Ballhausen additionally emphasizes the need to focus on quality of life in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.